Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36905345/
We assessed the effect of semaglutide 2.4 and 1.7 mg versus placebo on weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in the STEP 6 trial. Adults...
Conclusion: Overweight and obesity can have a negative impact on WRQOL and HRQOL. Our results demonstrate that in people from East Asia with overweight or obesity, treatment with once-weekly subcutaneous semaglutide 2.4 mg, in addition to a reduced caloric diet and increased physical activity, improved aspects of WRQOL and HRQOL,...
-
Endocrinologist Nation3yrKey Points • Source: Clinical Obesity • Conclusions/Relevance: “Treatment with semaglutide 2.4 mg improved aspects of WRQOL [work-related quality of life] and HRQOL [health-related quality of life] in people from East Asia with overweight/obesity.” • In Show More
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats
Source : https://www.sciencedirect.com/science/article/pii/S0753332223003232?via=ihub
Empagliflozin distinctly modulates the lipidome of rat white adipose tissue depots. * This drug induces a strong anti-inflammatory effect in rat visceral fat. * Empagliflozin reduces M1 and M2 macrophage...
Conclusions/Relevance: Our data highlighted differences in the VAT and SAT lipidomes, inflammatory profiles and lipolytic function, which suggest a distinct metabolism of these two white adipose tissue depots after the empagliflozin treatment.
GLP-1/GIP analogues: potential impact in the landscape of obesity pharmacotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36927378/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Expert Opinion: GLP-1R mimetics are often discontinued within 24-months, owing to gastrointestinal side-effects, meaning long-term application of these agents in obesity is questioned. Combined GIPR/GLP-1R agonism appears to induce fewer side-effects, indicating GLP-1R/GIPR co-agonists may be more suitable for enduring obesity management....
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects - Clinical Pharmacokinetics
Source : https://link.springer.com/article/10.1007/s40262-023-01223-9
Background Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting period of ≥ 30 min. This trial compared the recommended dosing...
Conclusion: This trial supports dosing oral semaglutide in accordance with prescribing information, which requires dosing in the fasting state.
User evaluation of a mobile education application for the management of metabolic syndrome among cancer survivors
Source : https://www.ejoncologynursing.com/article/S1462-3889(23)00010-8/fulltext
Both cancer survivors and oncology nurse specialists scored the area of functionality as the highest. * Both cancer survivors and oncology nurse specialists scored the area of engagement as the...
Conclusions: Metabolic syndrome in cancer survivors can be effectively managed by using the educational application developed in this study by improving the shortcomings of the app for cancer survivors.